Binding of CCCTC-binding factor in vivo to the region located between Rep* and the C promoter of Epstein–Barr virus is unaffected by CpG methylation and does not correlate with Cp activity

References

1. Altiok E., Minarovits J., Hu L. F., Contreras-Brodin B., Klein G., Ernberg I. 1992; Host-cell-phenotype-dependent control of the BCR2/BWR1 promoter complex regulates the expression of Epstein–Barr virus nuclear antigens 2–6. Proc Natl Acad Sci U S A 89:905–909 [CrossRef]
   [Google Scholar]
2. Baer R., Bankier A. T., Biggin M. D., Deininger P. L., Farrel P. J., Gibson T. G., Hatfull G., Hudson G. S., Satchwell S. C. other authors 1984; DNA sequence and expression of the B95-8 Epstein–Barr virus genome. Nature 310:207–211 [CrossRef]
   [Google Scholar]
3. Bakos A., Banati F., Koroknai A., Takacs M., Salamon D., Minarovits-Kormuta S., Schwarzmann F., Wolf H., Niller H. H., Minarovits J. 2007; High resolution analysis of CpG methylation and in vivo protein–DNA interactions at the alternative Epstein–Barr virus latency promoters Qp and Cp in the nasopharyngeal carcinoma cell line C666-1. Virus Genes 35:195–202 [CrossRef]
   [Google Scholar]
4. Banati F., Koroknai A., Salamon D., Takacs M., Minarovits-Kormuta S., Wolf H., Niller H. H., Minarovits J. 2008; CpG-methylation silences the activity of the RNA polymerase III transcribed EBER-1 promoter of Epstein–Barr virus. FEBS Lett 582:705–709 [CrossRef]
   [Google Scholar]
5. Busson P., Ganem G., Flores P., Muqneret F., Clausse B., Caillou B., Braham K., Wakasugi H., Lipinski M., Tursz T. 1988; Establishment and characterization of three transplantable EBV-containing nasopharyngeal carcinomas. Int J Cancer 42:599–606 [CrossRef]
   [Google Scholar]
6. Chau C. M., Zhang X. Y., McMahon S. B., Lieberman P. M. 2006; Regulation of Epstein–Barr virus latency type by the chromatin boundary factor CTCF. J Virol 80:5723–5732 [CrossRef]
   [Google Scholar]
7. Cheung S. T., Huang D. P., Hui A. B., Lo K. W., Ko C. W., Tsang Y. S., Wong N., Whitney B. M., Lee J. C. 1999; Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein–Barr virus. Int J Cancer 83:121–126 [CrossRef]
   [Google Scholar]
8. Day L., Chau C. M., Nebozhyn M., Rennekamp A. J., Showe M., Lieberman P. M. 2007; Chromatin profiling of Epstein–Barr virus latency control region. J Virol 81:6389–6401 [CrossRef]
   [Google Scholar]
9. Ernberg I., Falk K., Minarovits J., Busson P., Tursz T., Masucci M. G., Klein G. 1989; The role of methylation in the phenotype-dependent modulation of Epstein–Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein–Barr virus. J Gen Virol 70:2989–3002 [CrossRef]
   [Google Scholar]
10. Falk K. I., Szekely L., Aleman A., Ernberg I. 1998; Specific methylation patterns in two control regions of Epstein–Barr virus latency: the LMP-1-coding upstream regulatory region and an origin of DNA replication (oriP). J Virol 72:2969–2974
    [Google Scholar]
11. Fejer G., Koroknai A., Banati F., Györy I., Salamon D., Wolf H., Niller H. H., Minarovits J. 2008; Latency type-specific distribution of epigenetic marks at the alternative promoters Cp and Qp of Epstein–Barr virus. J Gen Virol 89:1364–1370 [CrossRef]
    [Google Scholar]
12. Filippova G. N. 2008; Genetics and epigenetics of the multifunctional protein CTCF. Curr Top Dev Biol 80:337–360
    [Google Scholar]
13. Gerle B., Koroknai A., Fejer G., Bakos A., Banati F., Szenthe K., Wolf H., Niller H. H., Minarovits J., Salamon D. 2007; Acetylated histone H3 and H4 mark the upregulated LMP2A promoter of Epstein–Barr virus in lymphoid cells. J Virol 81:13242–13247 [CrossRef]
    [Google Scholar]
14. Gregory C. D., Rowe M., Rickinson A. B. 1990; Different Epstein–Barr virus–B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J Gen Virol 71:1481–1495 [CrossRef]
    [Google Scholar]
15. Jones M. D., Foster L., Sheedy T., Griffin B. E. 1984; The EB virus genome in Daudi Burkitt's lymphoma cells has a deletion similar to that observed in a non-transforming strain (P3HR-1) of the virus. EMBO J 3:813–821
    [Google Scholar]
16. Kavathas P., Bach F. H., DeMars R. 1980; Gamma ray-induced loss of expression of HLA and glyoxalase I alleles in lymphoblastoid cells. Proc Natl Acad Sci U S A 77:4251–4255 [CrossRef]
    [Google Scholar]
17. Lenoir G. M., Vuillaume M., Bonnardel C. 1985; The use of lymphomatous and lymphoblastoid cell lines in the study of Burkitt's lymphoma. IARC Sci Publ 60:309–318
    [Google Scholar]
18. Liebowitz D. 1998; Epstein–Barr virus pathogenesis. In Human Tumor Viruses . pp 173–199Edited by McCance. Washington, DC: American Society for Microbiology;
19. Minarovits J., Minarovits-Kormuta S., Ehlin-Henriksson B., Falk K., Klein G., Ernberg I. 1991; Host cell phenotype-dependent methylation patterns of Epstein–Barr virus DNA. J Gen Virol 72:1591–1599 [CrossRef]
    [Google Scholar]
20. Minarovits J., Hu L. F., Marcsek Z., Minarovits-Kormuta S., Klein G., Ernberg I. 1992; RNA polymerase III-transcribed EBER 1 and 2 transcription units are expressed and hypomethylated in the major Epstein–Barr virus-carrying cell types. J Gen Virol 73:1687–1692 [CrossRef]
    [Google Scholar]
21. Mukhopadhyay R., Yu W., Whitehead J., Xu J., Lezcano M., Pack S., Kanduri C., Kanduri M., Ginjala V. other authors 2004; The binding sites for the chromatin insulator protein CTCF map to DNA methylation-free domains genome-wide. Genome Res 14:1594–1602 [CrossRef]
    [Google Scholar]
22. Niller H. H., Salamon D., Takacs M., Uhlig J., Wolf H., Minarovits J. 2001; Protein–DNA interaction and CpG methylation at rep*vIL-10p of latent Epstein–Barr virus genomes in lymphoid cell lines. Biol Chem 382:1411–1419
    [Google Scholar]
23. Niller H. H., Salamon D., Ilg K., Koroknai A., Banati F., Bauml G., Rücker O. L., Schwarzmann F., Wolf H., Minarovits J. 2003; The in vivo binding site for oncoprotein c-Myc in the promoter for Epstein–Barr virus (EBV) encoding RNA (EBER) 1 suggests a specific role for EBV in lymphomagenesis. Med Sci Monit 9:1–9
    [Google Scholar]
24. Ohlsson R., Renkawitz R., Lobanenkov V. 2001; CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease. Trends Genet 17:520–527 [CrossRef]
    [Google Scholar]
25. Robertson K. D., Ambinder R. F. 1997; Methylation of the Epstein–Barr virus genome in normal lymphocytes. Blood 90:4480–4484
    [Google Scholar]
26. Robertson K. D., Hayward S. D., Ling P. D., Samid D., Ambinder R. F. 1995; Transcriptional activation of the Epstein–Barr virus latency C promoter after 5-azacytidine treatment: evidence that demethylation at a single CpG site is crucial. Mol Cell Biol 15:6150–6159
    [Google Scholar]
27. Salamon D., Takacs M., Myöhänen S., Marcsek Z., Berencsi G., Minarovits J. 2000; De novo DNA methylation at nonrandom founder sites 5′ from an unmethylated minimal origin of DNA replication in latent Epstein–Barr virus genomes. Biol Chem 381:95–105
    [Google Scholar]
28. Salamon D., Takacs M., Ujvari D., Uhlig J., Wolf H., Minarovits J., Niller H. H. 2001; Protein–DNA binding and CpG methylation at nucleotide resolution of latency-associated promoters Qp, Cp and LMP1p of Epstein–Barr virus. J Virol 75:2584–2596 [CrossRef]
    [Google Scholar]
29. Salamon D., Takacs M., Schwarzmann F., Wolf H., Minarovits J., Niller H. H. 2003; High-resolution methylation analysis and in vivo protein–DNA binding at the promoter of the viral oncogene LMP2A in B cell lines carrying latent Epstein–Barr virus genomes. Virus Genes 27:57–66 [CrossRef]
    [Google Scholar]
30. Schaefer B. C., Strominger J. L., Speck S. H. 1997; Host-cell-determined methylation of specific Epstein–Barr virus promoters regulates the choice between distinct viral latency programs. Mol Cell Biol 17:364–377
    [Google Scholar]
31. Takacs M., Salamon D., Myöhänen S., Li H., Segesdi J., Ujvari D., Uhlig J., Niller H. H., Wolf H. other authors 2001; Epigenetics of latent Epstein–Barr virus genomes: high resolution methylation analysis of the bidirectional promoter region of latent membrane protein 1 and latent membrane protein 2B genes. Biol Chem 382:699–705
    [Google Scholar]
32. Tao Q., Robertson K. D., Manns A., Hildesheim A., Ambinder R. F. 1998; The Epstein–Barr virus major latent promoter Qp is constitutively active, hypomethylated, and methylation sensitive. J Virol 72:7075–7083
    [Google Scholar]
33. Walls D., Perricaudet M. 1991; Novel downstream elements upregulate transcription initiated from an Epstein–Barr virus latent promoter. EMBO J 10:143–151
    [Google Scholar]
34. Woisetschlaeger M., Strominger J. L., Speck S. H. 1989; Mutually exclusive use of viral promoters in Epstein–Barr virus latently infected lymphocytes. Proc Natl Acad Sci U S A 86:6498–6502 [CrossRef]
    [Google Scholar]